Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antimalarial Drug Resistance Profiling of Plasmodium falciparum Infections in India Using Next-Generation Sequencing.
Kale S, Uplekar SM, Bandyopadhyay N, Rao PN, Ali SZ, Sharma SK, Tandel N, Patel A, Singh R, Dank A, Ravishankaran S, Lakshmi Priya GS, Asokan A, Eapen A, Singh OP, Carlton JM, Mallick PK. Kale S, et al. Among authors: bandyopadhyay n. medRxiv [Preprint]. 2023 Apr 9:2023.04.08.23288321. doi: 10.1101/2023.04.08.23288321. medRxiv. 2023. PMID: 37066213 Free PMC article. Preprint.
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.
Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR. Lim EA, et al. Among authors: bandyopadhyay n. Clin Genitourin Cancer. 2023 Jun;21(3):366-375. doi: 10.1016/j.clgc.2023.02.010. Epub 2023 Feb 28. Clin Genitourin Cancer. 2023. PMID: 36948922 Clinical Trial.
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.
Nahi H, Usmani SZ, Mateos MV, van de Donk NWCJ, Oriol A, Plesner T, Bandyopadhyay N, Hellemans P, Tromp B, Nnane I, Zemlickis D, Chari A, Moreau P. Nahi H, et al. Among authors: bandyopadhyay n. Leuk Lymphoma. 2023 Feb;64(2):468-472. doi: 10.1080/10428194.2022.2148221. Epub 2023 Jan 2. Leuk Lymphoma. 2023. PMID: 36593729 Clinical Trial. No abstract available.
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Felip E, et al. Among authors: bandyopadhyay n. Cancer Chemother Pharmacol. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. Epub 2022 Mar 17. Cancer Chemother Pharmacol. 2022. PMID: 35298698 Free PMC article. Clinical Trial.
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies.
Brahmer JR, Johnson ML, Cobo M, Viteri S, Sarto JC, Sukari A, Awad MM, Salgia R, Papadimitrakopoulou VA, Rajan A, Bandyopadhyay N, Allred AJ, Wade M, Mason GE, Zudaire E, Knoblauch RE, Stone N, Lorenzi MV, Hassan R. Brahmer JR, et al. Among authors: bandyopadhyay n. JTO Clin Res Rep. 2020 Oct 5;2(2):100103. doi: 10.1016/j.jtocrr.2020.100103. eCollection 2021 Feb. JTO Clin Res Rep. 2020. PMID: 34589981 Free PMC article.
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.
Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Lauer P, Brockstedt D, Patricia D, Wade M, Zudaire E, Bandyopadhyay N, Parasrampuria DA, Girgis S, Mason GE, Knoblauch RE, Stone N, Infante JR, Gottardis MM, Fong L. Drake CG, et al. Among authors: bandyopadhyay n. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):219-228. doi: 10.1038/s41391-021-00402-8. Epub 2021 Jul 13. Prostate Cancer Prostatic Dis. 2022. PMID: 34257408 Free PMC article.
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N. Chi KN, et al. Among authors: bandyopadhyay n. J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29. J Clin Oncol. 2021. PMID: 33914595 Clinical Trial.
53 results